A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms NIMBLe
- 06 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2018 Status changed from not yet recruiting to recruiting.
- 20 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.